BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD5492 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD5492\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06916806-5372@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:AZD5492: Phase 1 readout est. (NCT06916806)
DESCRIPTION:AZD5492\, phase 1\, Systemic Lupus Erythematosus.\nStudy: A Stu
 dy to Investigate Safety\, Tolerability\, Pharmacokinetics\, and Pharmacod
 ynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus
  or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.\nEstimated
  primary completion: 5 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azd5492#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06916806
URL:https://assetmemo.bio/drug/azd5492#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06542250-5372@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:AZD5492: Phase 1/2 readout est. (NCT06542250)
DESCRIPTION:AZD5492\, phase 1/2.\nStudy: A Study to Evaluate Safety\, PK\, 
 PD and Efficacy of AZD5492\, a T Cell-engaging Antibody Targeting CD20 in 
 Subjects With R/R B-Cell Malignancies.\nEstimated primary completion: 18 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd5492
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 42250
URL:https://assetmemo.bio/drug/azd5492#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
